Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Hepatitis B reactivation after lamivudine.

× No keyword cloud information.

14 in total

1. A multicenter study evaluation of the digene hybrid capture II signal amplification technique for detection of hepatitis B virus DNA in serum samples and testing of EUROHEP standards.

Authors: H G Niesters; M Krajden; L Cork; M de Medina; M Hill; E Fries; A D Osterhaus
Journal: J Clin Microbiol Date: 2000-06 Impact factor: 5.948

2. Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-L-2',3'-dideoxy-3'-thiacytidine.

Authors: R W King; S K Ladner; T J Miller; K Zaifert; R B Perni; S C Conway; M J Otto
Journal: Antimicrob Agents Chemother Date: 1998-12 Impact factor: 5.191

3. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication.

Authors: S K Ladner; M J Otto; C S Barker; K Zaifert; G H Wang; J T Guo; C Seeger; R W King
Journal: Antimicrob Agents Chemother Date: 1997-08 Impact factor: 5.191

4. Hepatitis B core-related antigen: a strong indicator for cessation of nucleos(t)ide analog therapy in patients with chronic hepatitis B.

Authors: Akihiro Matsumoto
Journal: J Gastroenterol Date: 2016-09-24 Impact factor: 7.527

Review 5. Lamivudine. A review of its therapeutic potential in chronic hepatitis B.

Authors: B Jarvis; D Faulds
Journal: Drugs Date: 1999-07 Impact factor: 9.546

6. Natural YMDD-motif mutants affect clinical course of lamivudine in chronic hepatitis B.

Authors: You-Wen Tan; Yun Ye; Guo-Hong Ge; Wei Zhao; Jian-He Gan; Yun Zhao; Zhi-Lin Niu; Dong-Jun Zhang; Li Chen; Xue-Jun Yu; Li-Jun Yang
Journal: World J Gastroenterol Date: 2015-02-21 Impact factor: 5.742

7. Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B.

Authors: S G Lim; C T Wai; A Rajnakova; T Kajiji; R Guan
Journal: Gut Date: 2002-10 Impact factor: 23.059

8. Pharmacodynamics of (-)-beta-2',3'-dideoxy-3'-thiacytidine in chronically virus-infected woodchucks compared to its pharmacodynamics in humans.

Authors: S J Hurwitz; B C Tennant; B E Korba; J L Gerin; R F Schinazi
Journal: Antimicrob Agents Chemother Date: 1998-11 Impact factor: 5.191

9. Preemptive use of lamivudine in breast cancer patients carrying hepatitis B virus undergoing cytotoxic chemotherapy: a longitudinal study.

Authors: Meng-Shen Dai; Pei-Fen Wu; Jang-Jih Lu; Rong-Yaun Shyu; Tsu-Yi Chao
Journal: Support Care Cancer Date: 2004-03 Impact factor: 3.603

10. Long-term alpha interferon and lamivudine combination therapy in non-responder patients with anti-HBe-positive chronic hepatitis B: results of an open, controlled trial.

Authors: M Francesca Jaboli; Carlo Fabbri; Stefania Liva; Francesco Azzaroli; Giovanni Nigro; Silvia Giovanelli; Francesco Ferrara; Anna Miracolo; Sabrina Marchetto; Marco Montagnani; Antonio Colecchia; Davide Festi; Letizia Bacchi Reggiani; Enrico Roda; Giuseppe Mazzella
Journal: World J Gastroenterol Date: 2003-07 Impact factor: 5.742